Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira (Nasdaq: PCRX) said it received a Paragraph IV Certification Notice from Qilu Pharmaceutical (Hainan) Co., Ltd., which filed an ANDA with the FDA seeking approval of a generic version of EXPAR EL. Qilu alleges invalidity or noninfringement of 18 Orange Book-listed patents (U.S. Patent Nos. 11,033,495 through 12,370,142).
Pacira says the contested patents belong to two families expiring on January 22, 2041 and July 2, 2044. Pacira intends to enforce its IP and has 45 days to sue, which would trigger an automatic 30‑month FDA stay on Qilu’s ANDA approval under Hatch‑Waxman.
Pacira BioSciences (NASDAQ: PCRX) will present new real-world and health-economic data for EXPAREL at the AMCP Nexus 2025 Annual Meeting, Oct 27–30 in National Harbor, MD. Presentations on Oct 29 (12:00–1:00 p.m. ET) include results from the multicenter prospective IGOR registry and three posters evaluating EXPAREL's association with pain, opioid use, function, length of stay, healthcare utilization, and costs in total knee and outpatient shoulder arthroplasty settings.
Abstracts are available in the Journal of Managed Care + Specialty Pharmacy supplement.
Pacira BioSciences (Nasdaq: PCRX) said it received a Paragraph IV Certification Notice Letter from The WhiteOak Group, which filed an ANDA with the FDA claiming a generic version of EXPAREL.
WhiteOak disputes claims of 19 EXPAREL patents listed in the Orange Book and asserts they are invalid, unenforceable, or not infringed. Pacira identified two patent families with expiration dates of January 22, 2041 and July 2, 2044. Pacira has 45 days from receipt to sue; filing would trigger an automatic 30-month stay of FDA approval under Hatch-Waxman.
Pacira BioSciences (NASDAQ: PCRX) will present new 3-year clinical data for investigational PCRX-201 (enekinragene inzadenovec), a high-capacity adenovirus serotype 5 gene therapy for knee osteoarthritis, at ACR Convergence 2025 in Chicago.
The poster reports sustained improvements in pain and function from a Phase 1 trial and lists safety observations; a Phase 2 ASCEND study is currently underway. Presentation by Stanley Cohen, MD is scheduled for Tuesday, October 28, 10:30 a.m.–12:30 p.m. CT.
Pacira BioSciences (NASDAQ: PCRX) announced on October 3, 2025 that it granted inducement equity awards on October 2, 2025 to 15 new employees under its Amended and Restated 2014 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Six employees received stock options for an aggregate of 18,000 shares (10-year term; exercise price $24.58; four-year vesting with 25% at one year). Fifteen employees received restricted stock units totaling 32,600 shares (vest annually in four equal installments beginning Oct 1, 2026). Vesting is subject to continued employment and award agreements.
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has granted inducement awards to nine new employees under its Amended and Restated 2014 Inducement Plan. The awards, approved by the People & Compensation Committee on September 3, 2025, include:
- Stock Options: Six employees received options to purchase 13,000 shares at $27.18 per share, with a 10-year term and four-year vesting schedule
- Restricted Stock Units (RSUs): Nine employees received 18,100 RSUs, vesting annually in four equal installments starting September 1, 2026
Pacira BioSciences (Nasdaq: PCRX) reported Q2 2025 financial results with total revenues of $181.1 million. Key product sales included EXPAREL at $142.9 million, ZILRETTA at $31.3 million, and iovera° at $5.6 million. The company reported a net loss of $4.8 million ($0.11 per share) and adjusted EBITDA of $54.3 million.
Notable developments include surpassing 50% enrollment in the Phase 2 ASCEND study for PCRX-201, securing a new $300 million revolving credit facility, and entering a strategic collaboration with Johnson & Johnson MedTech. The company also received a $28.3 million favorable court ruling payment and strengthened its patent portfolio. Pacira updated its 2025 guidance, narrowing total revenue to $730-750 million and increasing non-GAAP gross margin to 78-80%.
The company repurchased 2.0 million shares at an average price of $25.59 per share, totaling $50.0 million.Pacira BioSciences (NASDAQ: PCRX), a leader in non-opioid pain therapies, will release its second quarter 2025 financial results after U.S. markets close on Tuesday, August 5, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET the same day. Participants can pre-register for the Q&A session via telephone, while the webcast will be accessible through the "Events" page on Pacira's investor website. A replay will be available for approximately two weeks following the call.
Pacira BioSciences (NASDAQ: PCRX) has announced a strategic collaboration with Johnson & Johnson MedTech to expand the market reach of ZILRETTA, their extended-release treatment for osteoarthritis knee pain. The partnership aims to leverage J&J's specialized early intervention sales force to co-promote the treatment.
The collaboration aligns with Pacira's 5x30 strategy and is expected to significantly expand access across the 7 million intra-articular knee injections administered annually in the U.S. The partnership will extend ZILRETTA's reach beyond orthopedic practices into sports medicine, pain management, and rheumatology specialties.
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, announced inducement grants to seven new employees on July 2, 2025. The awards include stock options for 3,500 shares to one employee and restricted stock units (RSUs) for 12,300 shares to seven employees.
The stock options have a 10-year term with a four-year vesting schedule, starting at 25% after the first year, followed by quarterly installments. The options' exercise price is set at $23.21 per share. The RSUs vest annually in four equal installments beginning July 1, 2026. All awards require continued employment with Pacira.